Bypassing the Bottlenecks: Multi-Modality Considerations for Next-Gen Cell and Gene Therapy, Upcoming Webinar Hosted by Xtalks

In this webinar, learn how integrated analytical strategies can support cell and gene therapy development across different modalities. The featured speakers will discuss how flow cytometry, genomics and bioanalysis can be used together to characterize cellular phenotype, genetic modifications and therapeutic activity. Attendees will also explore approaches to assay standardization, data integration and global deployment across complex clinical trials.

TORONTO, Sept. 2, 2026 /PRNewswire/ -- Cell and gene therapies (CGTs) are redefining the future of medicine, offering transformative treatment options across oncology, rare diseases, hematology and regenerative medicine. However, as these complex "living drugs" advance through clinical development, sponsors face increasing challenges in demonstrating safety, identity, purity, potency and long-term efficacy while meeting evolving regulatory expectations.

In this webinar, the featured speakers will explore how a multi-modality analytical strategy can help accelerate CGT development and overcome critical translational bottlenecks. Attendees will gain an overview of today's cell and gene therapy landscape, including key distinctions between cell therapies, such as CAR-T and hematopoietic stem cell therapies, and gene therapies, including AAV-based and RNA therapeutics. The session will highlight how specialized technologies, including flow cytometry, genomics and bioanalytical (BioA) testing, work together to provide a comprehensive understanding of therapeutic products. Participants will learn how these complementary approaches can be used to assess cellular phenotype and function, characterize genetic modifications, evaluate therapeutic activity and generate the integrated datasets needed to support clinical and regulatory success.

In addition, the session will address the operational and scientific challenges of implementing complex characterization strategies across global clinical trials. Experts will share practical considerations for assay standardization, data integration and global deployment to help ensure consistency, scalability and study success across regions.

Register for this webinar to discover how an integrated, multi-omic approach can bridge the gap between molecular design and cellular function, enabling more informed decision-making, reducing development risk and supporting the successful advancement of next-generation CGTs from discovery through commercialization.

Join experts from Cerba Research, Kirsty Maclean, Global Head of Research & Development; and Karthikeyan Devaraju, Senior Scientist, Cell & Gene Therapy, for the live webinar on Wednesday, September 30, 2026, at 11am EDT (5pm CEST / EU-Central).

For more information, or to register for this event, visit Bypassing the Bottlenecks: Multi-Modality Considerations for Next-Gen Cell and Gene Therapy.

ABOUT XTALKS

Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.

To learn more about Xtalks, visit www.xtalks.com

For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]

SOURCE Xtalks